ADI-001 Clinical Data and Safety Profile - ADI-001 demonstrated rapid and sustained reductions in SLEDAI-2K and PGA across all patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)[5,18] - All five LN patients achieved renal responses, including three complete renal responses and Definition of Remission in Systemic Lupus Erythematosus (DORIS) remissions[5,34] - ADI-001 showed a well-tolerated safety profile, with no ≥Grade 2 Cytokine Release Syndrome (CRS) or Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)[5,18] - All seven patients discontinued immunosuppressants and tapered corticosteroids to zero or physiological levels[5,18] - Clear evidence of immune reset was observed, with subsequent emergence of naïve B cell repertoire following a single treatment[5,18] ADI-001 Autoimmune Program and Pipeline - Adicet Bio is developing a broad pipeline of allogeneic γδ1 T cell therapies for autoimmune diseases and cancer[8] - ADI-001 is currently in clinical trials for LN & SLE, Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)/Stiff Person Syndrome (SPS), Anti-Neutrophil Cytoplasmic Autoantibody (ANCA)-Associated Vasculitis (AAV), and Rheumatoid Arthritis (RA)[8] - Adicet Bio anticipates SLE and LN clinical updates in the first half of 2026 and plans to initiate a pivotal study in LN or LN/SLE in the same period[11] ADI-212 Oncology Program - ADI-212, a PSMA-targeted therapy, is planned for regulatory filing in the first quarter of 2026, with initial clinical data expected in the second half of 2026 for metastatic castration-resistant prostate cancer (mCRPC)[8] Financial Status - As of June 30, 2025, Adicet Bio had approximately $125 million in cash and cash equivalents[12]